Human sTRAIL Receptor-1, also known as DR4 (Death Receptor-4), is a member of the TNF receptor family. This Human sTRAIL Receptor-1 is a 22.7 kDa protein containing 215 amino acid residues comprising the extracellular domain of TRAIL Receptor-1. It was produced inE.coli.

Description:

CD4 is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. It was discovered in the late 1970s and was originally known as leu-3 and T4 (after the OKT4 monoclonal antibody that reacted with it) before being named CD4 in 1984. In humans, the CD4 protein is encoded by the CD4 gene.

If this material is not to be used for coating or labeling (or other applications requiring carrier free material), the addition of 0.1% BSA to dilution buffers or dilution in sterile culture media is recommended to enhance stability and minimize absorption to vial. Ideally, maintain stock >10ug/ml.

Supplied:

Lyophilized protein.

Purity:

>95% by SDS-Page analysis. Endotoxin level is less than 0.1ng per ug (1EU/ug).

Reconstitution:

The lyophilized protein soluble in water and most aqueous buffers. The lyophilized powder should first be quick spun in vial, then reconstituted in water to a concentration of 0.1-1.0mg/ml. Allow to set at least 30 minutes at 4℃. If desired, can centrifuge for 1 minute at 1000 rpm to concentrate material in vial.

Biological Activity:

Determined by its inhibitory effect of IL-8 production in human PBMC by human sTRAIL/Apo2L. 95% inhibition (100 ng/ml of s TRAIL/Apo2L) was reached using a concentration of 100 ng/ml of sTRAIL Receptor-1.

Storage:

The lyophilized powder, though stable at room temperature for a few weeks, is best stored dessicated at -20℃. Reconstituted sTrail Receptor-1 should be stored in working aliquots at -20℃. Avoid Frequent Freeze-THAW Cycles.